ReNeuron’s AGM trading update highlights a busy six months ahead for the group. We anticipate IND approval to commence a Phase III trial in stroke before the end of 2017, enabling ReNeuron to commence the trial in early 2018. Phase I data from the ongoing Phase I/II trial in retinitis pigmentosa as well as filing for a Phase II trial in cone-rod dystrophy is also anticipated later this year. Positive developments from the programmes should be a share price catalyst. We remain update and look for ....
06 Sep 2017
N+1 Singer - ReNeuron Group - AGM trading update; busy 6 months ahead
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - ReNeuron Group - AGM trading update; busy 6 months ahead
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
06 Sep 2017 -
Author:
Sheena Berry -
Pages:
3
ReNeuron’s AGM trading update highlights a busy six months ahead for the group. We anticipate IND approval to commence a Phase III trial in stroke before the end of 2017, enabling ReNeuron to commence the trial in early 2018. Phase I data from the ongoing Phase I/II trial in retinitis pigmentosa as well as filing for a Phase II trial in cone-rod dystrophy is also anticipated later this year. Positive developments from the programmes should be a share price catalyst. We remain update and look for ....